CA2369284C - Three-dimensional structures containing hyaluronic acid derivatives obtained by the supercritical antisolvent technique - Google Patents
Three-dimensional structures containing hyaluronic acid derivatives obtained by the supercritical antisolvent technique Download PDFInfo
- Publication number
- CA2369284C CA2369284C CA002369284A CA2369284A CA2369284C CA 2369284 C CA2369284 C CA 2369284C CA 002369284 A CA002369284 A CA 002369284A CA 2369284 A CA2369284 A CA 2369284A CA 2369284 C CA2369284 C CA 2369284C
- Authority
- CA
- Canada
- Prior art keywords
- hyaluronic acid
- dimensional structures
- derivatives
- antisolvent
- structures according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical class CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 title claims abstract description 68
- 238000001808 supercritical antisolvent technique Methods 0.000 title 1
- 238000000034 method Methods 0.000 claims abstract description 56
- 239000012296 anti-solvent Substances 0.000 claims abstract description 31
- 238000001556 precipitation Methods 0.000 claims abstract description 18
- 238000001356 surgical procedure Methods 0.000 claims abstract description 5
- 239000000243 solution Substances 0.000 claims description 34
- 229920002674 hyaluronan Polymers 0.000 claims description 31
- 229960003160 hyaluronic acid Drugs 0.000 claims description 31
- 230000008569 process Effects 0.000 claims description 30
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 29
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims description 20
- -1 aliphatic alcohols Chemical class 0.000 claims description 15
- 239000002904 solvent Substances 0.000 claims description 15
- 239000000010 aprotic solvent Substances 0.000 claims description 12
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical class OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 12
- 229910002092 carbon dioxide Inorganic materials 0.000 claims description 11
- 229920000642 polymer Polymers 0.000 claims description 11
- 150000002148 esters Chemical class 0.000 claims description 10
- 238000011068 loading method Methods 0.000 claims description 10
- 239000012716 precipitator Substances 0.000 claims description 10
- 239000002244 precipitate Substances 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 9
- 210000000988 bone and bone Anatomy 0.000 claims description 8
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 8
- 239000003960 organic solvent Substances 0.000 claims description 8
- 230000032050 esterification Effects 0.000 claims description 7
- 238000005886 esterification reaction Methods 0.000 claims description 7
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 claims description 6
- 102000008186 Collagen Human genes 0.000 claims description 6
- 108010035532 Collagen Proteins 0.000 claims description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 6
- 229920001436 collagen Polymers 0.000 claims description 6
- 238000002347 injection Methods 0.000 claims description 6
- 239000007924 injection Substances 0.000 claims description 6
- 239000001384 succinic acid Substances 0.000 claims description 6
- 229920002683 Glycosaminoglycan Polymers 0.000 claims description 5
- 239000013543 active substance Substances 0.000 claims description 5
- 150000001875 compounds Chemical class 0.000 claims description 5
- 239000000499 gel Substances 0.000 claims description 5
- 238000003306 harvesting Methods 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 5
- 229920001059 synthetic polymer Polymers 0.000 claims description 5
- 210000001519 tissue Anatomy 0.000 claims description 5
- GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 claims description 4
- 229920001817 Agar Polymers 0.000 claims description 4
- 229920000936 Agarose Polymers 0.000 claims description 4
- 229920002101 Chitin Polymers 0.000 claims description 4
- 229920001661 Chitosan Polymers 0.000 claims description 4
- 229920002148 Gellan gum Polymers 0.000 claims description 4
- GQPLMRYTRLFLPF-UHFFFAOYSA-N Nitrous Oxide Chemical compound [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 claims description 4
- 229920002230 Pectic acid Polymers 0.000 claims description 4
- 239000008272 agar Substances 0.000 claims description 4
- 229920000615 alginic acid Polymers 0.000 claims description 4
- 235000010443 alginic acid Nutrition 0.000 claims description 4
- 125000001931 aliphatic group Chemical group 0.000 claims description 4
- 125000003118 aryl group Chemical group 0.000 claims description 4
- 238000004113 cell culture Methods 0.000 claims description 4
- 239000001913 cellulose Substances 0.000 claims description 4
- 229920002678 cellulose Polymers 0.000 claims description 4
- 125000000623 heterocyclic group Chemical group 0.000 claims description 4
- 229920001206 natural gum Polymers 0.000 claims description 4
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 claims description 4
- 239000001814 pectin Substances 0.000 claims description 4
- 235000010987 pectin Nutrition 0.000 claims description 4
- 229920003175 pectinic acid Polymers 0.000 claims description 4
- 239000010318 polygalacturonic acid Substances 0.000 claims description 4
- 150000004804 polysaccharides Polymers 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- 229920001285 xanthan gum Polymers 0.000 claims description 4
- 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 claims description 3
- 102100031614 Ciliary neurotrophic factor Human genes 0.000 claims description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 3
- 150000001298 alcohols Chemical class 0.000 claims description 3
- 239000001569 carbon dioxide Substances 0.000 claims description 3
- 239000003102 growth factor Substances 0.000 claims description 3
- 229910001385 heavy metal Chemical class 0.000 claims description 3
- 239000004745 nonwoven fabric Substances 0.000 claims description 3
- 229920001343 polytetrafluoroethylene Polymers 0.000 claims description 3
- 239000004810 polytetrafluoroethylene Substances 0.000 claims description 3
- 102000004169 proteins and genes Human genes 0.000 claims description 3
- 108090000623 proteins and genes Proteins 0.000 claims description 3
- 125000006850 spacer group Chemical group 0.000 claims description 3
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims description 2
- 108010025020 Nerve Growth Factor Proteins 0.000 claims description 2
- 102000015336 Nerve Growth Factor Human genes 0.000 claims description 2
- 229920000954 Polyglycolide Polymers 0.000 claims description 2
- 229920002472 Starch Polymers 0.000 claims description 2
- 230000001476 alcoholic effect Effects 0.000 claims description 2
- 150000001299 aldehydes Chemical class 0.000 claims description 2
- 239000000783 alginic acid Substances 0.000 claims description 2
- 229960001126 alginic acid Drugs 0.000 claims description 2
- 150000004781 alginic acids Chemical class 0.000 claims description 2
- 239000003242 anti bacterial agent Substances 0.000 claims description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 2
- 229940088710 antibiotic agent Drugs 0.000 claims description 2
- 235000019445 benzyl alcohol Nutrition 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 238000013130 cardiovascular surgery Methods 0.000 claims description 2
- 210000000845 cartilage Anatomy 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 238000010924 continuous production Methods 0.000 claims description 2
- 229920001577 copolymer Polymers 0.000 claims description 2
- 238000004132 cross linking Methods 0.000 claims description 2
- 150000004985 diamines Chemical class 0.000 claims description 2
- 230000002526 effect on cardiovascular system Effects 0.000 claims description 2
- 230000002500 effect on skin Effects 0.000 claims description 2
- 239000000945 filler Substances 0.000 claims description 2
- 230000000762 glandular Effects 0.000 claims description 2
- 150000004676 glycans Polymers 0.000 claims description 2
- 150000004820 halides Chemical class 0.000 claims description 2
- 230000002440 hepatic effect Effects 0.000 claims description 2
- 229930195733 hydrocarbon Natural products 0.000 claims description 2
- 150000002430 hydrocarbons Chemical class 0.000 claims description 2
- 230000000921 morphogenic effect Effects 0.000 claims description 2
- 230000003387 muscular Effects 0.000 claims description 2
- 229920005615 natural polymer Polymers 0.000 claims description 2
- 210000005036 nerve Anatomy 0.000 claims description 2
- 229940053128 nerve growth factor Drugs 0.000 claims description 2
- 239000001272 nitrous oxide Substances 0.000 claims description 2
- 239000004033 plastic Substances 0.000 claims description 2
- 229920003023 plastic Polymers 0.000 claims description 2
- 229920000747 poly(lactic acid) Polymers 0.000 claims description 2
- 229920002627 poly(phosphazenes) Polymers 0.000 claims description 2
- 239000004633 polyglycolic acid Substances 0.000 claims description 2
- 239000004626 polylactic acid Substances 0.000 claims description 2
- 229920001282 polysaccharide Polymers 0.000 claims description 2
- 239000005017 polysaccharide Substances 0.000 claims description 2
- 239000002243 precursor Substances 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 230000008929 regeneration Effects 0.000 claims description 2
- 238000011069 regeneration method Methods 0.000 claims description 2
- 229920005989 resin Polymers 0.000 claims description 2
- 239000011347 resin Substances 0.000 claims description 2
- 210000004872 soft tissue Anatomy 0.000 claims description 2
- 239000008107 starch Substances 0.000 claims description 2
- 235000019698 starch Nutrition 0.000 claims description 2
- 150000005846 sugar alcohols Polymers 0.000 claims description 2
- 150000001991 dicarboxylic acids Chemical class 0.000 claims 1
- 229920002635 polyurethane Polymers 0.000 claims 1
- 239000004814 polyurethane Substances 0.000 claims 1
- 230000000087 stabilizing effect Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 4
- 239000007788 liquid Substances 0.000 description 8
- 238000012360 testing method Methods 0.000 description 7
- 230000008901 benefit Effects 0.000 description 5
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000012620 biological material Substances 0.000 description 3
- 239000003638 chemical reducing agent Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000017423 tissue regeneration Effects 0.000 description 3
- 239000002699 waste material Substances 0.000 description 3
- 201000009859 Osteochondrosis Diseases 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000000061 acid fraction Substances 0.000 description 2
- 230000010478 bone regeneration Effects 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 239000007791 liquid phase Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 239000002077 nanosphere Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000003019 stabilising effect Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- IDCPFAYURAQKDZ-UHFFFAOYSA-N 1-nitroguanidine Chemical compound NC(=N)N[N+]([O-])=O IDCPFAYURAQKDZ-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 108010003272 Hyaluronate lyase Proteins 0.000 description 1
- 102000001974 Hyaluronidases Human genes 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- AEMOLEFTQBMNLQ-WAXACMCWSA-N alpha-D-glucuronic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-WAXACMCWSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000002429 anti-coagulating effect Effects 0.000 description 1
- 210000001742 aqueous humor Anatomy 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 210000001520 comb Anatomy 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 239000002360 explosive Substances 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 229960002773 hyaluronidase Drugs 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229920002492 poly(sulfone) Polymers 0.000 description 1
- 229920005749 polyurethane resin Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 238000005204 segregation Methods 0.000 description 1
- 239000011265 semifinished product Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 210000003954 umbilical cord Anatomy 0.000 description 1
- 210000004127 vitreous body Anatomy 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- D—TEXTILES; PAPER
- D01—NATURAL OR MAN-MADE THREADS OR FIBRES; SPINNING
- D01F—CHEMICAL FEATURES IN THE MANUFACTURE OF ARTIFICIAL FILAMENTS, THREADS, FIBRES, BRISTLES OR RIBBONS; APPARATUS SPECIALLY ADAPTED FOR THE MANUFACTURE OF CARBON FILAMENTS
- D01F9/00—Artificial filaments or the like of other substances; Manufacture thereof; Apparatus specially adapted for the manufacture of carbon filaments
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
- C08B37/0072—Hyaluronic acid, i.e. HA or hyaluronan; Derivatives thereof, e.g. crosslinked hyaluronic acid (hylan) or hyaluronates
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J9/00—Working-up of macromolecular substances to porous or cellular articles or materials; After-treatment thereof
- C08J9/28—Working-up of macromolecular substances to porous or cellular articles or materials; After-treatment thereof by elimination of a liquid phase from a macromolecular composition or article, e.g. drying of coagulum
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
- C08L5/08—Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2201/00—Foams characterised by the foaming process
- C08J2201/04—Foams characterised by the foaming process characterised by the elimination of a liquid or solid component, e.g. precipitation, leaching out, evaporation
- C08J2201/054—Precipitating the polymer by adding a non-solvent or a different solvent
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2203/00—Foams characterized by the expanding agent
- C08J2203/08—Supercritical fluid
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/54—Improvements relating to the production of bulk chemicals using solvents, e.g. supercritical solvents or ionic liquids
Landscapes
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Polymers & Plastics (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Materials Engineering (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Textile Engineering (AREA)
- Materials For Medical Uses (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT1999PD000071A IT1306644B1 (it) | 1999-04-08 | 1999-04-08 | Strutture tridimensionali comprendenti derivati dell'acido ialuronicoottenibili mediante la tecnica antisolvente supercritico. |
| ITPD99A000071 | 1999-04-08 | ||
| PCT/EP2000/003081 WO2000061675A1 (en) | 1999-04-08 | 2000-04-06 | Three-dimensional structures containing hyaluronic acid derivatives obtained by the supercritical antisolvent technique |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2369284A1 CA2369284A1 (en) | 2000-10-19 |
| CA2369284C true CA2369284C (en) | 2010-01-12 |
Family
ID=11392548
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002369284A Expired - Fee Related CA2369284C (en) | 1999-04-08 | 2000-04-06 | Three-dimensional structures containing hyaluronic acid derivatives obtained by the supercritical antisolvent technique |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US7087745B1 (enExample) |
| EP (1) | EP1169387B1 (enExample) |
| JP (1) | JP2002541888A (enExample) |
| AT (1) | ATE234341T1 (enExample) |
| AU (1) | AU765563B2 (enExample) |
| CA (1) | CA2369284C (enExample) |
| DE (1) | DE60001640T2 (enExample) |
| ES (1) | ES2194727T3 (enExample) |
| IT (1) | IT1306644B1 (enExample) |
| WO (1) | WO2000061675A1 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITPD20010032A1 (it) | 2001-02-09 | 2002-08-09 | Fidia Advanced Biopolymers Srl | Innesti ingegnerizzati per la riparazione di difetti osteocondrali |
| RU2220729C2 (ru) * | 2002-01-31 | 2004-01-10 | Общество с ограниченной ответственностью "Научный Центр системных исследований и технологий 2000" | Гелевая композиция, используемая в стоматологии |
| FR2850282B1 (fr) | 2003-01-27 | 2007-04-06 | Jerome Asius | Implant injectable a base de ceramique pour le comblement de rides, depressions cutanees et cicatrices, et sa preparation |
| ZA200507803B (en) * | 2003-04-04 | 2007-03-28 | Bayco Tech Ltd | Vascular stent |
| US8512730B2 (en) * | 2004-07-12 | 2013-08-20 | Isto Technologies, Inc. | Methods of tissue repair and compositions therefor |
| US8192759B2 (en) * | 2004-07-12 | 2012-06-05 | Isto Technologies, Inc. | Matrix made of polyester polymers entangled with hyaluronic polymers useful for supporting tissue repair |
| US8444968B2 (en) * | 2005-12-07 | 2013-05-21 | Isto Technologies, Inc. | Cartilage repair methods |
| ITPD20060219A1 (it) | 2006-05-31 | 2007-12-01 | Fidia Farmaceutici | Composizioni farmaceutiche contenenti acido ialuronico solfatato nel trattamento dell'osteoartrosi |
| JP5758797B2 (ja) | 2008-04-04 | 2015-08-05 | ユニバーシティ・オブ・ユタ・リサーチ・ファウンデイション | アルキル化半合成グリコサミノグリカンエーテルならびにその製造および使用方法 |
| EP2324064B1 (en) | 2008-09-02 | 2017-11-08 | Tautona Group LP | Threads of hyaluronic acid and/or derivatives thereof, methods of making thereof and uses thereof |
| JP6062917B2 (ja) | 2011-03-23 | 2017-01-18 | ザ ユニバーシティ オブ ユタ リサーチ ファウンデイション | 泌尿器科の炎症の治療及び予防の方法 |
| US10245306B2 (en) | 2012-11-16 | 2019-04-02 | Isto Technologies Ii, Llc | Flexible tissue matrix and methods for joint repair |
| CZ2013913A3 (cs) * | 2013-11-21 | 2015-06-03 | Contipro Biotech S.R.O. | Objemný nanovlákenný materiál na bázi kyseliny hyaluronové, jejích solí nebo jejich derivátů, způsob jeho přípravy, způsob jeho modifikace, modifikovaný nanovlákenný materiál, nanovlákenný útvar a jejich použití |
| US10179191B2 (en) | 2014-10-09 | 2019-01-15 | Isto Technologies Ii, Llc | Flexible tissue matrix and methods for joint repair |
| CN105734604B (zh) * | 2016-03-03 | 2017-08-25 | 武汉大学 | 一种立体复合多糖凝胶及其电化学3d打印制备方法和应用 |
| WO2018053111A1 (en) | 2016-09-15 | 2018-03-22 | University Of Utah Research Foundation | In situ gelling compositions for the treatment or prevention of inflammation and tissue damage |
| CN111228653A (zh) | 2018-11-13 | 2020-06-05 | 格莱科米拉治疗公司 | 用电离辐射加强癌症治疗的方法 |
| JP2019104937A (ja) * | 2019-04-04 | 2019-06-27 | イビデン株式会社 | ヒアルロン酸及び／又はその塩の粉末 |
| JP2019104938A (ja) * | 2019-04-04 | 2019-06-27 | イビデン株式会社 | ヒアルロン酸及び／又はその塩の粉末 |
| CN110423291B (zh) * | 2019-09-06 | 2020-06-16 | 焦点生物医药有限公司 | 一种速溶透明质酸钠制备方法 |
| WO2025072953A1 (en) * | 2023-09-28 | 2025-04-03 | University Of Massachusetts | Composition for depolymerizing resins and methods of accomplishing the same |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE7811306L (sv) | 1978-11-01 | 1980-05-02 | Rothman Gunnvor | Antikoagulationsmedel samt sett for dess framstellning |
| CH666897A5 (fr) | 1983-10-11 | 1988-08-31 | Fidia Spa | Fractions d'acide hyaluronique non inflammatoire, procedes et compositions pharmaceutiques. |
| US4851521A (en) * | 1985-07-08 | 1989-07-25 | Fidia, S.P.A. | Esters of hyaluronic acid |
| FR2584728B1 (fr) | 1985-07-12 | 1987-11-20 | Choay Sa | Procede de sulfatation de glycosaminoglycanes et de leurs fragments |
| IT1198449B (it) | 1986-10-13 | 1988-12-21 | F I D I Farmaceutici Italiani | Esteri di alcoli polivalenti di acido ialuronico |
| DK505588D0 (da) | 1988-02-26 | 1988-09-09 | Jesper Hamburger | Middel og anvendelse af samme |
| IT1219587B (it) | 1988-05-13 | 1990-05-18 | Fidia Farmaceutici | Polisaccaridi carbossiilici autoreticolati |
| IT1219942B (it) | 1988-05-13 | 1990-05-24 | Fidia Farmaceutici | Esteri polisaccaridici |
| IT1247175B (it) | 1991-04-19 | 1994-12-12 | Fidia Spa | Procedimento per la purificazione di acido ialuronico e frazione di acido ialuronico puro per uso oftalmico. |
| IT1254704B (it) * | 1991-12-18 | 1995-10-09 | Mini Ricerca Scient Tecnolog | Tessuto non tessuto essenzialmente costituito da derivati dell'acido ialuronico |
| IT1260148B (it) | 1992-04-17 | 1996-03-28 | Fidia Spa | Impiego di preparazioni di acido ialuronico per la formazione di tessuto osseo |
| ITPD940054A1 (it) | 1994-03-23 | 1995-09-23 | Fidia Advanced Biopolymers Srl | Polisaccaridi solfatati |
| EP0817620B1 (en) | 1995-03-28 | 2002-01-30 | Fidia Advanced Biopolymers, S.R.L. | Nanospheres comprising a biocompatible polysaccharide |
| US5833891A (en) | 1996-10-09 | 1998-11-10 | The University Of Kansas | Methods for a particle precipitation and coating using near-critical and supercritical antisolvents |
| IT1287698B1 (it) | 1996-08-29 | 1998-08-18 | Fidia Advanced Biopolymers Srl | Fili da sutura essenzialmente costituiti da derivati esterei dello acido ialuronico |
| DK0971961T3 (da) | 1997-04-04 | 2003-03-24 | Fidia Advanced Biopolymers Srl | N-sulfaterede hyaluronsyreforbindelser, derivater deraf og en fremgangsmåde til deres fremstilling |
-
1999
- 1999-04-08 IT IT1999PD000071A patent/IT1306644B1/it active
-
2000
- 2000-04-06 JP JP2000611610A patent/JP2002541888A/ja active Pending
- 2000-04-06 DE DE60001640T patent/DE60001640T2/de not_active Expired - Lifetime
- 2000-04-06 US US09/958,144 patent/US7087745B1/en not_active Expired - Fee Related
- 2000-04-06 AU AU49126/00A patent/AU765563B2/en not_active Ceased
- 2000-04-06 AT AT00931057T patent/ATE234341T1/de active
- 2000-04-06 CA CA002369284A patent/CA2369284C/en not_active Expired - Fee Related
- 2000-04-06 WO PCT/EP2000/003081 patent/WO2000061675A1/en not_active Ceased
- 2000-04-06 ES ES00931057T patent/ES2194727T3/es not_active Expired - Lifetime
- 2000-04-06 EP EP00931057A patent/EP1169387B1/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| WO2000061675A1 (en) | 2000-10-19 |
| DE60001640T2 (de) | 2004-03-25 |
| JP2002541888A (ja) | 2002-12-10 |
| EP1169387A1 (en) | 2002-01-09 |
| AU765563B2 (en) | 2003-09-25 |
| EP1169387B1 (en) | 2003-03-12 |
| CA2369284A1 (en) | 2000-10-19 |
| ATE234341T1 (de) | 2003-03-15 |
| AU4912600A (en) | 2000-11-14 |
| ES2194727T3 (es) | 2003-12-01 |
| DE60001640D1 (de) | 2003-04-17 |
| ITPD990071A1 (it) | 2000-10-08 |
| US7087745B1 (en) | 2006-08-08 |
| IT1306644B1 (it) | 2001-10-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2369284C (en) | Three-dimensional structures containing hyaluronic acid derivatives obtained by the supercritical antisolvent technique | |
| Li et al. | Design of 3D polycaprolactone/ε-polylysine-modified chitosan fibrous scaffolds with incorporation of bioactive factors for accelerating wound healing | |
| Wang et al. | Bioactive silk fibroin scaffold with nanoarchitecture for wound healing | |
| Rad et al. | Calendula officinalis extract/PCL/Zein/Gum arabic nanofibrous bio-composite scaffolds via suspension, two-nozzle and multilayer electrospinning for skin tissue engineering | |
| Cardea et al. | Generation of chitosan nanoporous structures for tissue engineering applications using a supercritical fluid assisted process | |
| Yin et al. | Plant-derived nanocellulose as structural and mechanical reinforcement of freeze-cast chitosan scaffolds for biomedical applications | |
| US9044410B2 (en) | Filament based on hyaluronic acid in the form of free acid and method for obtaining it | |
| Sadeghi et al. | Electrospun polyvinyl alcohol/gelatin/chondroitin sulfate nanofibrous scaffold: Fabrication and in vitro evaluation | |
| Liu et al. | Nano-fibrous and ladder-like multi-channel nerve conduits: Degradation and modification by gelatin | |
| US9683011B2 (en) | Controlled cross-linking processing of proteins | |
| CN106075568B (zh) | 一种组织修复用可降解纳米短纤维材料及其制备方法和应用 | |
| EP2318062B1 (en) | New biomaterials, their preparation by electrospinning and their use in the biomedical and surgical field | |
| Hu et al. | Facile fabrication of poly (L-lactic acid) microsphere-incorporated calcium alginate/hydroxyapatite porous scaffolds based on Pickering emulsion templates | |
| Li et al. | Fabrication, characterization, and in vitro evaluation of biomimetic silk fibroin porous scaffolds via supercritical CO2 technology | |
| Feng et al. | Injectable self-crosslinking hyaluronic acid/silk fibroin blend hydrogel based on disulfide bond | |
| CN114470330A (zh) | 用于组织填充的重组胶原蛋白凝胶微粒及其制备方法 | |
| CA2369275C (en) | Process for the preparation of autocrosslinked compounds of hyaluronic acid and the derivatives thereof by the supercritical antisolvent technique | |
| CN113249327B (zh) | 一种用于肿瘤细胞培养的三维细胞培养支架及其制备方法 | |
| Ilomuanya | Hydrogels as biodegradable biopolymer formulations | |
| CN114848908B (zh) | 一种神经导管的制备方法 | |
| Meesa et al. | Optimization of Gelatin Fibrous Scaffold Properties by PCL and CMC by Using Electrospinning Technique | |
| Banu et al. | Natural biomaterials for tissue engineering and regenerative medicine | |
| CN106474562A (zh) | 透明质酸钠／β‑磷酸三钙多孔复合材料的制备方法 | |
| Pal et al. | Natural Polymers: Tissue Engineering | |
| Oliveira et al. | Chapter VIII Promising biomolecules |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20190408 |